Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis of Diversely Substituted Diethyl (Pyrrolidin-2-Yl)Phosphonates

  • Bagán, Andrea
  • López-Ruiz, Alba
  • Abás, Sònia|||0000-0002-3005-3539
  • Molins Grau, Elies|||0000-0003-1012-0551
  • Pérez, Belén|||0000-0001-5801-1704
  • Muneta-Arrate, Itziar
  • Callado, Luis F.|||0000-0001-9941-012X
  • Escolano, Carmen|||0000-0002-9117-8239
Imidazoline I receptors (I-IR) are untapped therapeutic targets lacking a structural description. Although the levels of I-IR are dysregulated in a plethora of illnesses, the arsenal of ligands that can modulate I-IR is limited. In this framework, we have reported several new structural families embodying the iminophosphonate functional group that have an excellent affinity and selectivity for I-IR, and selected members have demonstrated relevant pharmacological properties in murine models of neurodegeneration and Alzheimer's disease. Starting with these iminophosphonates, we continued to exploit their high degree of functionalization through a short and efficient synthesis to access unprecedented 2,3-di, 2,2,3-tri, 2,3,4-tri, and 2,2,3,4-tetrasubstituted diethyl (pyrrolidine-2-yl) phosphonates. The stereochemistry of the new compounds was unequivocally characterized by X-ray crystallographic analyses. Two selected compounds with structural features shared with the starting products were pharmacologically evaluated, allowing us to deduce the required key structural motifs for biologically active aminophosphonate derivatives.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beta-hydroxybutyrate counteracts the deleterious effects of a saturated high-fat diet on synaptic AMPAR receptors and cognitive performance

  • Rojas, Rocío|||0000-0002-0509-1023
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Castellanos, Aida
  • Griego, Ernesto
  • Martínez, Marc
  • de Dios Navarro-López, Juan
  • Jiménez-Díaz, Lydia|||0000-0001-9121-0334
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
  • Soto del Cerro, David
  • Castillo, Pablo E.
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Casals, Nuria|||0000-0002-6719-4300
  • Fadó, Rut|||0000-0002-3293-2342
The ketogenic diet -high in fat and low in carbohydrates- and intermittent fasting have gained popularity not only for weight management but also for their potential to delay cognitive decline associated with neurodegenerative diseases and aging. However, adherence to these diets remains low due to their restrictive nature and undesirable side effects. Both dietary approaches stimulate hepatic production of ketone bodies, primarily β-hydroxybutyrate (BHB), which serves as an alternative energy source for neurons. Here, we investigated whether BHB supplementation could mitigate AMPA receptor trafficking impairments, synaptic dysfunction, and cognitive decline induced by metabolic challenges such as a saturated fat-rich diet. Our results show that, in cultured primary cortical neurons, exposure to palmitic acid decreases surface levels of glutamate GluA1-containing AMPA receptors, whereas unsaturated fatty acids and BHB increase these levels. Furthermore, physiological concentrations of BHB (1-2 mM) countered the adverse effects of palmitic acid on synaptic GluA1 and GluA2 levels in hippocampal neurons, restoring AMPA receptor-mediated synaptic transmission. In hippocampal slices, BHB also reversed palmitate-induced impairments in excitability and synaptic plasticity (long-term potentiation; LTP). Additionally, daily intragastric administration of BHB (100 mg/kg/day for two months) prevented deficits in recognition and spatial memory induced by a saturated fat-rich diet (49% of calories from fat) in mice. In summary, our findings underscore the significant impact of fatty acids and ketone bodies on AMPA receptor abundance, synaptic function, and neuroplasticity, shedding light on the potential use of BHB as a dietary supplement to counteract cognitive impairments linked to metabolic diseases.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2<i>H</i>-pyrrol-2-yl) phosphonates as Imidazoline <i>I</i><sub>2</sub> receptor ligands with anti-Alzheimer and analgesic properties

  • Bagán, Andrea
  • López Ruiz, Alba
  • Abás Prades, Sònia
  • Ruiz Cantero, M. Carmen
  • Vasilopoulou, Foteini
  • Taboada Jara, Teresa
  • Griñán Ferré, Christian
  • Pallàs, Mercè
  • Muguruza Millán, Carolina
  • Díez Alarcia, Rebeca
  • Callado Hernando, Luis Felipe
  • Entrena Fernández, José Manuel
  • Cobos del Moral, Enrique José
  • Pérez Fernández, Belén
  • Morales García, José A.
  • Molins, Elies
  • Jonghe, Steven De
  • Daelemans, Dirk
  • Brea Floriani, José Manuel
  • Val García, Cristina
  • Loza García, María Isabel
  • Hernández Hernández, Elena
  • García Sevilla, Jesús A.
  • García-Fuster, M. Julia
  • Díaz Navarro, Caridad
  • Fernández Godino, Rosario
  • Genilloud, Olga
  • Beljkaš, Milan
  • Oljačić, Slavica
  • Nikolic, Katarina
  • Escolano Mirón, Carmen
Imidazoline I2 receptors (I2-IRs) are altered in Alzheimer’s disease (AD) patients and are associated with analgesia. I2-IRs are not structurally described, and their pharmacological characterization relies on their modulation by highly affine ligands. Herein, we describe the synthesis of (3-phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates endowed with relevant affinities for I2-IRs in human brain tissues. The optimal ADME and pharmacokinetic profile of a selected compound, 12d, secured its in vivo exploration in a senescence accelerated prone 8 mice revealing improvement in the cognitive impairment and unveiling the mechanism of action by analyzing specific AD biomarkers. The treatment of a capsaicin-induced mechanical hypersensitivity murine model with 12d revealed analgesic properties devoid of motor coordination issues. The target engagement of 12d was demonstrated by suppression of the analgesic effect by pretreatment with idazoxan. Overall, 12d is a putative candidate for advancing preclinical phases and supports the modulation of I2-IRs as an innovative approach for therapeutics
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex differences in the antidepressant-like response and molecular events induced by the imidazoline-2 receptor agonist CR4056 in rats

  • Hernández Hernández, Elena
  • Ledesma-Corvi, S.
  • Yáñez-Gómez, Fernando
  • Garau, C.
  • Gálvez-Melero, Laura
  • Bagán, Andrea
  • Escolano, Carmen
  • García-Fuster, M. Julia
In searching for novel targets to design antidepressants, among the characterized imidazoline receptors (IR), I2 receptors are an innovative therapeutical approach since they are dysregulated in major depressive disorder and by classical antidepressant treatments. In fact, several I2 agonists have been characterized for their antidepressant-like potential, but the results in terms of efficacy were mixed and exclusively reported in male rodents. Since there are well-known sex differences in antidepressant-like efficacy, this study characterized the potential effects induced by two I2 drugs, CR4056 (i.e., most promising drug already in phase II clinical trial for its analgesic properties) and B06 (a compound from a new family of bicyclic α-iminophosphonates) under the stress of the forced-swim test in male and female rats exposed to early-life stress. Moreover, some hippocampal neuroplasticity markers related to the potential effects observed were also evaluated (i.e., FADD, p-ERK/ERK, mBDNF, cell proliferation: Ki-67 + cells). The main results replicated the only prior study reporting the efficacy of CR4056 in male rats, while providing new data on its efficacy in females, which was clearly dependent on prior early-life stress exposure. Moreover, B06 showed no antidepressant-like effects in male or female rats. Finally, CR4056 increased FADD content and decreased cell proliferation in hippocampus, without affecting p-ERK/t-ERK ratio and/or mBDNF content. Interestingly, these effects were exclusively observed in female rats, and independently of early-life conditions, suggesting some distinctive molecular underpinnings participating in the therapeutic response of CR4056 for both sexes. In conjunction, these results present CR4056 with an antidepressant-like potential, especially in female rats exposed to stress early in life, together with some neuronal correlates described in the context of these behavioral changes in females., This research was partly supported by several grants to MJG-F: PID2020-118582RB-I00 (MCIN/AEI/10.13039/501100011033) and PDR2020/14 (Comunitat Autonoma ` de les Illes Balears through the Direccio ´ General de Política Universitaria ` i Recerca with funds from the Tourist Stay Tax Law ITS 2017–006). Moreover, this study was also funded by PID2019-107991RB-I00 (MCIN/AEI) and PDC2022-133441- I00 (MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”) to CE. These entities had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The salaries of personnel were covered by several research programs: predoctoral scholarships to EH-H (FPI/2102/2018) from Consejería de Innovacion, ´ Investigacion ´ y Turismo del Gobierno de las Islas Baleares y del Fondo Social Europeo, who is currently funded by the Margarita Salas Program (Ministerio de Universidades; Plan de Recuperacion, ´ Transformacion ´ y Resilencia; NextGenerationEU) with the participation of the University of the Balearic Islands; JUNIOR Program to SL-C from “TALENT PLUS Construint Salut, Generant Valor” (IdISBa, GOIB); CG is funded by the María Zambrano Program (Ministerio de Universidades; Plan de Recuperacion, ´ Transformacion ´ y Resilencia; NextGenerationEU) at the University of the Balearic Islands; AB received financial support from Institute of Biomedicine UB_2018.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I<inf>2</inf> receptor ligands

  • Bagán, Andrea
  • Abás, Sònia
  • Palà Pujadas, Judith
  • Irisarri, Alba
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Muneta Arrate, Itziar
  • Muguruza, Carolina
  • Callado, Luis F.
  • Pérez, Belén
  • Molins, Elies
  • Morales García, José
  • Escolano, Carmen
Recent studies pointed out the modulation of imidazoline I2 receptors (I2-IR) by selective ligands as a putative strategy to face neurodegenerative diseases. Foregoing the classical 2-imidazoline/imidazole-containing I2-IR ligands, we report a family of bicyclic α-iminophosphonates endowed with high affinity and selectivity upon I2-IR and we advanced a representative compound B06 in preclinical phases. In this paper, we describe the synthetic possibilities of bicyclic α-iminophosphonates by exploring its ambivalent reactivity, leading to unprecedented molecules that showed promising activities as I2-IR ligands in human brain tissues and good BBB permeation capabilities. After in silico ADME prediction studies, we assessed the neuroprotective properties of selected compounds and beneficial effect in an in vitro model of Alzheimeŕs and Parkinson's disease. Along with their neuroprotective effect, compounds showed a potent anti-inflammatory response when evaluated in a neuroinflammation cellular model. Moreover, this is the first time that the neuroprotective effects of imidazoline I2-IR ligands in a transgenic Alzheimer's disease Caenorhabditis elegans strain are investigated. Using a thrashing assay, we found a significant cognition improvement in this in vivo model after treatment with the new bicyclic α-phosphoprolines. Therefore, our results confirmed the need of exploring structurally new I2-IR ligands and their potential for therapeutic strategies in neurodegeneration., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (Spain, PID2019-107991RB-I00, PID2022-1380790B-I00), Basque Government (IT-1211-19 and 1512-22), Generalitat de Catalunya (GC) (2021 SGR 00357) and PDC2022-133441-I00 (MCIN/AEI/ 10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR) and by UCM-Santander (PR44/21-29931 to J.A.M.-G.). The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434) under agreement CI18-00002. This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2020 research and innovation programme., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of Gadd45a Expression in Mice Leads to Cognitive and Synaptic Impairment Associated with Alzheimer’s Disease Hallmarks

  • Griñán-Ferré, Christian
  • Jarne-Ferrer, Júlia
  • Bellver-Sanchis, Aina
  • Ribalta-Vilella, Marta
  • Barroso, Emma
  • Salvador Sánchez, Jesús María
  • Jurado-Aguilar, Javier
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
  • Pallàs, Mercè
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Gadd45 genes have been implicated in survival mechanisms, including apoptosis, autophagy, cell cycle arrest, and DNA repair, which are processes related to aging and life span. Here, we analyzed if the deletion of Gadd45a activates pathways involved in neurodegenerative disorders such as Alzheimer’s Disease (AD). This study used wild-type (WT) and Gadd45a knockout (Gadd45a−/−) mice to evaluate AD progression. Behavioral tests showed that Gadd45a−/− mice presented lower working and spatial memory, pointing out an apparent cognitive impairment compared with WT animals, accompanied by an increase in Tau hyperphosphorylation and the levels of kinases involved in its phosphorylation in the hippocampus. Moreover, Gadd45a−/− animals significantly increased the brain’s pro-inflammatory cytokines and modified autophagy markers. Notably, neurotrophins and the dendritic spine length of the neurons were reduced in Gadd45a−/− mice, which could contribute to the cognitive alterations observed in these animals. Overall, these findings demonstrate that the lack of the Gadd45a gene activates several pathways that exacerbate AD pathology, suggesting that promoting this protein’s expression or function might be a promising therapeutic strategy to slow down AD progression., This research was funded by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) PID2021-122116OB-100 (M.V.-C.), PID2022-139016OA-100 (C.G.-F), and PDC2022-133441-100 (M.P.), Generalitat de Catalunya (2021 SGR 00357). This study was co-financed by Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092). A.B-S acknowledges the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) for her FI-SDUR fellowship (2021 FISDU 00182). This study was also partly supported by “ERDF A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and CIBER de Enfermedades Neurodegenerativas (CIBERNED) are a Carlos III Health Institute project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis of Diversely Substituted Diethyl (Pyrrolidin-2-Yl)Phosphonates

  • Bagán, Andrea
  • López Ruiz, Alba
  • Abás, Sònia
  • Molins, Elies
  • Pérez, Belén
  • Muneta Arrate, Itziar
  • Callado, Luis F.
  • Escolano, Carmen
Imidazoline I2 receptors (I2-IR) are untapped therapeutic targets lacking a structural description. Although the levels of I2-IR are dysregulated in a plethora of illnesses, the arsenal of ligands that can modulate I2-IR is limited. In this framework, we have reported several new structural families embodying the iminophosphonate functional group that have an excellent affinity and selectivity for I2-IR, and selected members have demonstrated relevant pharmacological properties in murine models of neurodegeneration and Alzheimer's disease. Starting with these iminophosphonates, we continued to exploit their high degree of functionalization through a short and efficient synthesis to access unprecedented 2,3-di, 2,2,3-tri, 2,3,4-tri, and 2,2,3,4-tetrasubstituted diethyl (pyrrolidine-2-yl) phosphonates. The stereochemistry of the new compounds was unequivocally characterized by X-ray crystallographic analyses. Two selected compounds with structural features shared with the starting products were pharmacologically evaluated, allowing us to deduce the required key structural motifs for biologically active aminophosphonate derivatives., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (Spain, PID2022-1380790B-I00 MICIU/AEI/10.13039/501100011033 and FEDER, UE and PDC2022-133441-I00 MICIU/AEI/10.13039/501100011033 Europea Next GenerationEU/PRTR), the Basque Government (IT1512/22) and Generalitat de Catalunya (2021 SGR 00357). Financial support was provided for A.L.-R. (PRE2022-105091 Ministerio de Ciencia e Innovación)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates as Imidazoline I2 Receptor Ligands with Anti-Alzheimer and Analgesic Properties

  • Bagán, Andrea
  • López Ruiz, Alba
  • Abás, Sònia
  • Ruiz Cantero, M. Carmen
  • Vasilopoulou, Foteini
  • Taboada Jara, Teresa
  • Griñán Ferré, Christian
  • Pallàs, Mercè
  • Muguruza, Carolina
  • Diez Alarcia, Rebeca
  • Callado, Luis F.
  • Entrena, José M.
  • Cobos, Enrique J.
  • Pérez, Belén
  • Morales García, José A.
  • Molins, Elies
  • De Jonghe, Steven
  • Daelemans, Dirk
  • Brea, José
  • Val, Cristina
  • Loza, M. Isabel
  • Hernández Hernández, Elena
  • García Sevilla, Jesús A.
  • García Fuster, M Julia
  • Díaz, Caridad
  • Fernández Godino, Rosario
  • Genilloud, Olga
  • Beljkaš, Milan
  • Oljačić, Slavica
  • Nikolic, Katarina
  • Escolano, Carmen
Imidazoline I2 receptors (I2-IRs) are altered in Alzheimer's disease (AD) patients and are associated with analgesia. I2-IRs are not structurally described, and their pharmacological characterization relies on their modulation by highly affine ligands. Herein, we describe the synthesis of (3-phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates endowed with relevant affinities for I2-IRs in human brain tissues. The optimal ADME and pharmacokinetic profile of a selected compound, 12d, secured its in vivo exploration in a senescence accelerated prone 8 mice revealing improvement in the cognitive impairment and unveiling the mechanism of action by analyzing specific AD biomarkers. The treatment of a capsaicin-induced mechanical hypersensitivity murine model with 12d revealed analgesic properties devoid of motor coordination issues. The target engagement of 12d was demonstrated by suppression of the analgesic effect by pretreatment with idazoxan. Overall, 12d is a putative candidate for advancing preclinical phases and supports the modulation of I2-IRs as an innovative approach for therapeutics., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (Spain, PID2022-1380790B-I00 to C.E., and PID2021-138079OB-I00 to M.P.; MICIU/AEI/10.13039/501100011033 and FEDER, UE; and PDC2022-133441-I00 to C.E.; MICIU/AEI/10.13039/501100011033 Europea Next GenerationEU/PRTR), Basque Government (IT-1512-22) and Generalitat de Catalunya (2021 SGR 00357). Financial support was provided for A.L.-R. (PRE2022-105091 ministerio de Ciencia e Innovación). E.H.-H. was first funded by the Margarita Salas Program (Ministerio de Universidades; Plan de Recuperación, Transformación y Resilencia; NextGenerationEU) with the participation of the University of the Balearic Islands, and currently holds grant FJC2022-048338-I, funded by MCIN/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. The authors acknowledge grant support from the Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health, Xunta de Galicia (ED431C 2022/20) and the European Regional Development Fund (ERDF). This study was partially supported by the Andalusian Regional Government (grant CTS-109). Authors also thank the support of the Unit of Excellence “UNETE” from the University of Granada (reference UCE-PP2017-05). M.B., S.O., and K.N. acknowledge the Ministry of Science, Technological Development and Innovation, Republic of Serbia through two Grant Agreements with University of Belgrade-Faculty of Pharmacy No. 451-03-65/2024-03/200161 and No. 451-03-66/2024-03/200161. A.L. thanks to Grant PRE2022-105091 funded by MICIU/AEI/10.13039/501100011033., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-based Therapy of Parkinson’s Disease

  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Schäker-Hübner, Linda
  • Diez-Iriepa, Daniel
  • Iriepa, Isabel
  • Siwek, Agata
  • Wolak, Małgorzata
  • Satała, Grzegorz
  • Bojarski, Andrzej J.
  • Doroz-Płonka, Agata
  • Handzlik, Jadwiga
  • Godyń, Justyna
  • Dallemagne, Patrick
  • Rochais, Christophe
  • Davis, Audrey
  • Since, Marc
  • Pérez, Belén
  • Bellver-Sanchis, Aina
  • Irisarri, Alba
  • Pallàs, Mercè
  • Solana-Manrique, Cristina
  • López-Muñoz, Francisco
  • Ismaili, Lhassane
  • Griñán-Ferré, Christian
  • Paricio, Nuria
  • K. Hansen, Finn
  • Więckowska, Anna
  • Marco-Contelles, José
This article belongs to the Special Issue 25th Anniversary of IJMS: Updates and Advances in Molecular Pathology, Diagnostics, and Therapeutics, Herein, we have identified the polyfunctionalized 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid derivative MTP150 for the treatment of neurodegenerative diseases owing to its efficacy in reducing protein aggregation, modulating matrix metalloproteinase activity, mitigating neuroinflammation, and enhancing DNA damage repair pathways across in vivo Caenorhabditis elegans models of Alzheimer’s disease, Parkinson’s disease (PD), and Huntington’s disease. Further experiments in an in vivo Drosophila model of PD showed that MTP150 increased motor performance, reduced oxidative stress levels, and restored mitochondrial function in model flies. In addition, MTP150 exhibited neuroprotective effects in PD model cells, thereby supporting its therapeutic potential for this disease., J.M.-C. thanks AEI (Government of Spain; Grant PID2019-105813RB-C21) and Comunidad de Madrid (IND2023/BMD-27036) for support. I.I. thanks AEI (Government of Spain; Grant PID2019-105813RB-C22) for support. A.P.-P. is grateful to Comunidad de Madrid (IND2023/BMD27036) for a fellowship. This work was supported by grants PID2022-139016OA-I00 and PDC2022-133441-I00, funded by MICIU/AEI/10.13039/501100011033 and FEDER, UE, awarded to C.G.-F. and M.P.; Generalitat de Catalunya (2021 SGR 00357) to CGF and MP; and University of Valencia (UVINV-AE-3664989) to NP. This study was co-financed by Secretaria d’Universitats i Recerca de Departament d’Empresa i Coneixement de la Generalitat de Catalunya 2022 (Producte 0092; Llavor 005 and 007; to CGF). The work of L.S.-H. and F.K.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), GRK2873 (494832089)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease

  • Bagán, Andrea
  • Morales García, José Ángel
  • Escolano, Carmen
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer’s disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson’s disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease

  • Bagán, Andrea
  • Rodriguez-Arévalo, Sergio
  • Taboada-Jara, Teresa
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Brocos Mosquera, Iria|||0000-0002-6471-4892
  • Callado, Luis F.|||0000-0001-9941-012X
  • Morales-García, José A.|||0000-0001-9008-0056
  • Pérez, Belén|||0000-0001-5801-1704
  • Díaz Navarro, Caridad|||0000-0003-1240-0143
  • Fernández-Godino, Rosario
  • Genilloud, Olga
  • Beljkas, Milan
  • Oljacic, Slavica
  • Nikolic, Katarina
  • Escolano, Carmen|||0000-0002-9117-8239
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer's disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson's disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d] imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer's disease

  • Bautista Aguilera, Óscar Mauricio|||0000-0002-1327-1681
  • Manik, Aleksandra
  • Diez Iriepa, Daniel|||0000-0002-8575-1246
  • Szałaj , Natalia
  • Marco Contelles, José Luis
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • Martínez Alonso, Borja
  • Guarnizo Herrero, Víctor|||0000-0001-9323-3388
  • Torrado Durán, Guillermo|||0000-0002-8865-2083
As part of a project aimed at the pharmacological optimization of Contilisant, herein we describe molecular modelling studies that led to the identification of MBA-159 as a new polyfunctionalized, multitarget-directed ligand and a promising drug candidate for the treatment of Alzheimer?s disease. We synthesized MBA-159 and conducted comprehensive in vitro and in vivo evaluations. In in vivo studies MBA-159 demonstrated favourable pharmacokinetics, anti-amnesic properties and significantly improved non-spatial memory (contextual and recognition memory) in a mouse model of scopolamine-induced amnesia. Additionally, MBA-159 showed a tendency to increase synaptic plasticity biomarkers and reduce neuroinflammatory trends (assessed by qPCR), as well as cognitive enhancement in a senescence-accelerated prone mouse 8 model., Ministerio de Ciencia e Innovación, Ministerio de Economía, Comercio y Empresa